<DOC>
	<DOC>NCT02495454</DOC>
	<brief_summary>GA101-miniCHOP regimen for the treatment of elderly unfit patients with diffuse large B-cell non-Hodgkin's lymphoma.</brief_summary>
	<brief_title>GA101-miniCHOP Regimen for the Treatment of Elderly Unfit Patients With Diffuse Large B-cell Non-Hodgkin's Lymphoma</brief_title>
	<detailed_description />
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma, Non-Hodgkin</mesh_term>
	<mesh_term>Lymphoma, B-Cell</mesh_term>
	<mesh_term>Lymphoma, Large B-Cell, Diffuse</mesh_term>
	<mesh_term>Obinutuzumab</mesh_term>
	<criteria>1. Histologically proven CD20 positive Diffuse Large Bcell Lymphoma and Follicular grade IIIB lymphoma, according to WHO classification (local pathologist) 2. Age ≥ 65 years 3. No previous treatment 4. CGA assessment performed before starting treatment 5. UNFIT patients defined as follows: Age &gt; 80 years with FIT profile, i.e. ADL =6 residual functions IADL=8 residual functions CIRS: no comorbidity of grade 34 and &lt;5 of grade 2 or Age &lt; 80 with UNFIT profile, i.e ADL &gt; 5 residual functions IADL &gt; 6 residual functions CIRS: no comorbidity of grade 34 and 58 comorbidities of grade 2 6. Ann Arbor Stage I with bulky, IIIV 7. At least one bidimensionally measurable lesion defined as &gt; 1.5 cm in its largest dimension on CT scan 8. ECOG performance status of 0, 1, or 2 9. Adequate hematologic function (unless caused by bone marrow infiltrate), defined as follows: Hemoglobin ≥ 10 g/dL Absolute neutrophil count ≥ 1.5 x 109/L Platelet count ≥ 100 x 109/L 10. LVEF &gt;50% 11. Ability and willingness to comply with the study protocol procedure 12. Life expectancy &gt; 6 months 13. Accessibility of patient for treatment and follow up 14. Written informed consent 1. History of severe allergic or anaphylactic reactions to humanized or murine monoclonal antibodies or known sensitivity or allergy to murine products 2. Contraindication to any of the individual components of CHOP, including prior receipt of anthracyclines 3. History of other malignancies within 5 years prior to study entry except for adequately treated carcinoma in situ of the cervix or basal or squamous cell skin cancer 4. Stage I without bulky 5. Patients with transformed lymphoma 6. Prior therapy for DLBCL, with the exception of nodal biopsy or local irradiation 7. Previous exposure to cytotoxic agents 8. Suspect or clinical evidence of CNS involvement by lymphoma 9. HBsAg, HCV or HIV positivity; isolated HBcAb positivity is accepted only with concomitant treatment with Lamivudine 10. AST /ALT &gt; twice upper the normal range; bilirubin &gt; twice upper the normal range; serum creatinine &gt; 2.5 mg /dl (unless these abnormalities were related to the lymphoma) 11. Evidence of any severe active acute or chronic infection 12. Concurrent comorbid medical condition which might exclude administration of full dose chemotherapy</criteria>
	<gender>All</gender>
	<minimum_age>65 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2016</verification_date>
</DOC>